Anja Rinke
University of Marburg
Internal medicineEndocrinologySurgeryPathologyOncologyRetrospective cohort studyPlaceboSomatostatinChemotherapyTolerabilityNeuroendocrine tumorsDiseaseTumor progressionSunitinibLanreotidePrimary tumorDacarbazineOctreotideGynecologyIn patientCancer researchMedicineGastroenterology
Publications 113
#1Sami Matrood (University of Marburg)H-Index: 1
#7Damiano Librizzi (University of Marburg)H-Index: 10
Last. Zoltan Kender (University Hospital Heidelberg)H-Index: 7
view all 12 authors...
#1Dominik ReherH-Index: 1
#2Uli FehrenbachH-Index: 5
Last. Anja RinkeH-Index: 22
view all 11 authors...
#1Sebastian KrugH-Index: 13
#2Marko DammH-Index: 2
Last. Anja RinkeH-Index: 22
view all 8 authors...
The systemic treatment of patients with pancreatic neuroendocrine tumors is based on placebo-controlled trials and long-established chemotherapy approaches. In addition, peptide receptor radionuclide therapy (PRRT) was approved as a parallel approach for pancreatic neuroendocrine tumors (NET), in addition to small bowel NET, after the NETTER-1 trial. The current ESMO and NCCN guidelines attempted to describe treatment algorithms for pancreatic NET based on the current data. In our survey, we rec...
Background The long-acting somatostatin analog lanreotide autogel is effective in the treatment of patients with neuroendocrine tumors. null null null null Objective To evaluate the long-term treatment response in patients with neuroendocrine tumors receiving lanreotide autogel in routine clinical practice. null null null null Methods Non-interventional, 24-month study in patients with neuroendocrine tumors treated with lanreotide autogel (NCT01840449). null null null null Results Patients (n=80...
#1Leonidas Apostolidis (University Hospital Heidelberg)H-Index: 6
#2Jörg Schrader (UHH: University of Hamburg)H-Index: 12
Last. Sebastian Krug (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 13
view all 5 authors...
Central nervous system (CNS) involvement by paraneoplastic syndromes, brain metastases, or leptomeningeal carcinomatosis (LC) in patients with neuroendocrine neoplasms (NEN) has only been described in individual case reports. We evaluated patients with LC in four neuroendocrine tumor (NET) centers (Halle/Saale, Hamburg, Heidelberg, and Marburg) and characterized them clinically. In the study, 17 patients with a LC were defined with respect to diagnosis, clinic, and therapy. The prognosis of a LC...
#1Anja Rinke (University of Marburg)H-Index: 22
#2Christoph J. Auernhammer (LMU: Ludwig Maximilian University of Munich)H-Index: 31
Last. Thomas M. Gress (University of Marburg)H-Index: 82
view all 14 authors...
Gastroenteropancreatic neuroendocrine neoplasia (GEPNEN) comprises clinically as well as prognostically diverse tumour entities often diagnosed at late stage. Current classification provides a uniform terminology and a Ki67-based grading system, thereby facilitating management. Advances in the study of genomic and epigenetic landscapes have amplified knowledge of tumour biology and enhanced identification of prognostic and potentially predictive treatment subgroups. Translation of this genomic a...
1 CitationsSource
#2Anja RinkeH-Index: 22
Last. Detlef K. Bartsch (University of Marburg)H-Index: 43
view all 6 authors...
Background Small intestinal neuroendocrine neoplasms (SI-NEN) are rare, and only about 40% of patients are diagnosed without distant metastases. Aim of the study was to identify prognostic factors in patients with potentially curative resected locoregional SI-NEN. Methods Patients with curative resected locoregional SI-NEN (ENETS stages I-III) were retrieved from a prospective data base. Demographic, surgical and pathological data of patients with and without disease recurrence were retrospectiv...
1 CitationsSource
#1Sebastian Krug (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 13
#2Jakob Garbe (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 3
Last. Jörg Schrader (UHH: University of Hamburg)H-Index: 12
view all 7 authors...
The treatment and monitoring of patients with neuroendocrine tumors (NET) has been a major challenge during the COVID-19 pandemic. In a survey, we investigated the influence of COVID-19 on the care of NET patients in the German speaking countries Germany, Austria and Switzerland. The multidisciplinarity of all treating physicians in the outpatient and inpatient sector was reflected in our survey. Furthermore, we were able to present findings pertaining to the university and non-university medica...
4 CitationsSource
#1Sebastian Krug (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 13
#2Julia Weissbach (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 2
Last. Patrick Michl (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 15
view all 10 authors...
Recently, we identified the homeodomain transcription factor Cut homeobox 1 (CUX1) as mediator of tumour de-differentiation and metastatic behaviour in human insulinoma patients. In insulinomas, CUX1 enhanced tumour progression by stimulating proliferation and angiogenesis in vitro and in vivo. In patients with non-functional pancreatic neuroendocrine tumours (PanNET), however, the impact of CUX1 remains to be elucidated. Here, we analysed CUX1 expression in two large independent cohorts (n = 43...
1 CitationsSource